Drug Type Small molecule drug |
Synonyms ABT-126 |
Target |
Action agonists |
Mechanism α7 receptor agonists(Neuronal acetylcholine receptor protein alpha-7 subunit agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H19N3OS |
InChIKeyQZDCYUCETTWCMO-FOOLLQQTSA-N |
CAS Registry1026134-63-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chanarin-Dorfman Syndrome | Phase 2 | United States | 01 Mar 2010 | |
Cognitive Dysfunction | Phase 2 | United States | 01 Mar 2010 | |
Schizophrenia | Phase 2 | United States | 01 Mar 2010 | |
Alzheimer Disease | Phase 2 | United States | 01 Oct 2009 | |
Alzheimer Disease | Phase 2 | Bulgaria | 01 Oct 2009 | |
Alzheimer Disease | Phase 2 | Czechia | 01 Oct 2009 | |
Alzheimer Disease | Phase 2 | Slovakia | 01 Oct 2009 | |
Alzheimer Disease | Phase 2 | South Africa | 01 Oct 2009 | |
Alzheimer Disease | Phase 2 | United Kingdom | 01 Oct 2009 |
Phase 2 | 432 | yvspbrpgae(bkzoahsxtu) = ccqwcladrz qabmebxftq (ybkbpmliau, 0.54) View more | Negative | 01 Nov 2016 | |||
Placebo | yvspbrpgae(bkzoahsxtu) = lvjpbfnika qabmebxftq (ybkbpmliau, 0.56) View more |